Chiasma, Inc. (NASDAQ:CHMA) Director Scott Minick bought 15,000 shares of the firm’s stock in a transaction dated Wednesday, September 20th. The shares were purchased at an average price of $2.38 per share, with a total value of $35,700.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Scott Minick also recently made the following trade(s):

  • On Thursday, September 21st, Scott Minick purchased 25,000 shares of Chiasma stock. The shares were bought at an average cost of $2.37 per share, for a total transaction of $59,250.00.

Shares of Chiasma, Inc. (NASDAQ:CHMA) opened at 2.40 on Friday. The company’s market capitalization is $58.46 million. Chiasma, Inc. has a one year low of $1.55 and a one year high of $3.71. The stock has a 50 day moving average price of $2.31 and a 200-day moving average price of $2.31.

ILLEGAL ACTIVITY NOTICE: “Scott Minick Buys 15,000 Shares of Chiasma, Inc. (CHMA) Stock” was posted by Daily Political and is the sole property of of Daily Political. If you are reading this piece of content on another website, it was copied illegally and republished in violation of United States and international trademark and copyright law. The original version of this piece of content can be read at https://www.dailypolitical.com/2017/09/24/scott-minick-buys-15000-shares-of-chiasma-inc-chma-stock.html.

Separately, ValuEngine raised Chiasma from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st.

About Chiasma

Chiasma, Inc is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body’s production of excess growth hormone.

Receive News & Ratings for Chiasma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chiasma Inc. and related companies with MarketBeat.com's FREE daily email newsletter.